Kyowa Kirin Co., Ltd. · TSE:4151
Kyowa Kirin — Kyowa Hakko Kirin — Q3 2013 Earnings Presentation
23 slides from Kyowa Kirin's earnings presentation, Oct 25, 2013
Slide 1: Third quarter results presentation FY ending December 2013
FY ending December 2013 Third quarter results presentation Kazuyoshi Tachibana Executive Managing Officer and CFO Kyowa Hakko Kirin Co., Ltd. October 25, 2013
Slide 2: Forward-looking statements
Forward-looking statements This document contains certain forward-looking statements relating to such items as the company’s (including its domestic and overseas subsidiaries) forecasts, targets and plans. These forward-looking statements are based upon information available to the company at the pr
Slide 3: Summary of Q3 results (consolidated)
Summary of Q3 results (consolidated)
Slide 4: Summary of Q3 results (consolidated)
Summary of Q3 results (consolidated) Sales and profits increased in Q3 driven by a good performance by pharmaceutical products in Japan, continued strong growth at ProStrakan, and further weakening of the yen FY2013 Rate of (Unit: ¥bn) FY 2012 Q3 FY 2013 Q3 Change Forecast progress Net sales 244.6 2
Slide 5: Analysis of YonY profit changes
Summary of Q3 consolidated results: Analysis of YonY profit changes ¥bn Q3 net income (total): Analysis of YonY changes Pharmaceuticals +¥2.2bn Kyowa Hakko Kirin (non-consol.) +¥3.8bn 26.0 (Introduction cost of Onglyza in 2012 ¥3.0bn) 24.0 ProStrakan -¥2.1bn (currency effects) Bio-Chemicals –¥0.9bn
Slide 6: Pharmaceuticals Business: Q3 results
Pharmaceuticals Business: Q3 results
Slide 7: Pharmaceuticals Business: Analysis of YonY profit changes
Pharmaceuticals Business: Q3 results: Analysis of YonY profit changes ～ ～ Net sales Consolidated operating income ～ ～ ～ FY12 Q3 ～ FY12 Q3 Domestic ～ ～ sales (parent) Exports Gross profits -0.3 -3 (Parent) +0.5 +5 Technology SG&A licensing (excl. R&D (parent) expenses) Overseas sales (including ProSt
Slide 8: Domestic sales of core pharmaceutical products
Domestic sales of core pharmaceutical products Domestic core pharmaceutical products on track to achieve 2013 full-year forecast despite impact of April 2012 reductions in NHI drug prices Jan. – Sept. Jan. – Sept. Change* Rate of Product name 2012 2013 (b)-(a) Reason for changes progress** Results (
Slide 9: Strengthening presence of NESP
Strengthening presence of NESP® Strong support from healthcare professionals as the easiest-to-use ESA* No. 1 ESA market share in Japan • The only long-lasting ESA that covers ESA SALES (Year) all renal anemia patients ranging from infants to adults and from pre-dialysis 2013** phase to dialysis pha
Slide 10: Contribution to cancer pain treatment
Contribution to cancer pain treatment The approval of ABSTRAL® fentanyl formulation makes it possible to consistently control persistent and breakthrough cancer pain and contribute to pallitative cancer treatment. • Cancer pain drug Treatment for breakthrough and persistent pain ABSTRAL® approved in
Slide 11: ProStrakan: Update
ProStrakan: Update Strong growth in ABSTRAL® sales, SANCUSO® launched in Europe Full year results from ProStrakan should make a positive contribution to consolidated Kyowa Hakko Kirin results ABSTRAL® ・Nine-month sales up 140% YonY ・Achieved 77.1％ of full year sales plan in first nine months SANCUSO
Slide 12: Bio-Chemicals Business: Q3 results
Bio-Chemicals Business: Q3 results
Slide 13: Bio-Chemicals Business: Analysis of YonY profit changes
Bio-Chemicals Business: Q3 results: Analysis of YonY profit changes Net sales Consolidated operating income ～ ～ FY12 Q3 57.4 FY12 Q3 ～ ～ Healthcare (parent) -0.7 Pharma/ Gross profits Industrial use (Parent) SG&A, SG&A (excl. R&D Overseas (excl. R&D expenses) sales expenses) Dai Ichi Fine Chemical -
Slide 14: Development Pipeline
KYOWA KIRIN Development Pipeline Seer ee eee ee ee copyright© 2008 Kyowa Hakko Kirin Co.,Ltd. All Rights Reserved
Slide 15: 2013 Q3 Progress in development pipeline
2013 Q3 Progress in development pipeline Application for approval in Japan for additional indication to maximize the value of POTELIGEO® Approvals for ABSTRAL® and NESP® progressing as planned Japan Application for additional indication for POTELIGEO® , a humanized anti-CCR4 monoclonal antibody (J
Slide 16: KRN23: Accelerating global development
KRN23: Accelerating global development License to develop and commercialize KRN23 with US-based company Ultragenyx Aiming to launch clinical trials for pediatric XLH* in 2014 Ultragenyx Pharmaceutical Inc. Business: Established in 2010, specializing in therapeutic drug development for rare metabolis
Slide 17: KRN23: Overview of development products
KRN23: Overview of development products KRN23: Fully human antibody targeting FGF23 Mechanism of action (1) KRN23 a therapeutic antibody that is designed to bind to FGF23, a biogenic factor that induces profound reductions in serum phosphate levels, thereby reducing the biologic activity of FGF23. (
Slide 18: Overview of development of outlicensed antibodies and biosimilars
Overview of development of outlicensed antibodies and biosimilars MEDI-563 Benralizumab Humanized anti-IL-5 receptor antibody AstraZeneca and MedImmune are conducting Phase II trials targeting asthma patients and Phase II trials targeting COPD patients FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd.
Slide 19: Inquiries: Corporate Communications Department
If you have any inquiries regarding this presentation please call: Corporate Communications Department, Kyowa Hakko Kirin Co., Ltd. Tel: +81-3-3282-0009
Slide 20: Appendix
KYOWA KIRIN Appendix eee copyright© 2008 Kyowa Hakko Kirin Co.,Ltd. All Rights Reserved
Slide 21: Recent events on in-licensed pipelines
Recent events on in-licensed pipelines ARQ 197 Promoting development of hepatocellular carcinoma in large Asian market Target Stage Status Remarks disease NSCLC EGFR-Wild Phase3 Discontinued Occurrence of interstitial lung disease in the study NSCLC EGFR-Mut. Phase2 On going EGFR-Mut. common among A
Slide 22: Development progress with outlicensed compounds
Development progress with outlicensed compounds Phase Name Partner Remarks I II III Cancer Tivozanib AVEO (VEGF receptor inhibitor) (KRN951) Asthma (Anti-IL-5R antibody) BenralizuMab MedImmune (KHK4563) (MEDI-563) POTELLIGENT® COPD KRN5500 DARA Peripheral neuropathy RGI2001 REGiMMUNE Phase1/2 Immuno
Slide 23: Currency effects
Currency effects Forex rates (period average) 2012 2013 YoY Jan. – Sept. Jan. – Sept. US$ ¥79 ¥95 +¥16 EUR ¥102 ¥125 +¥23 GBP ¥125 ¥147 +¥22 Currency effects 2013 Jan. – Sept. Currency effects (Year on year) Pharmaceuticals Bio-Chemicals Consolidated Net sales +¥5.7bn +¥4.4bn +¥10.2bn Operating +¥1.